Skip to main content
Premium Trial:

Request an Annual Quote

Benitec, Biomics Finalize Expressed RNAi Rx Collaboration for HBV

Premium

Australia’s Benitec said this week that it has entered into binding agreements with Chinese drug firm Biomics Biotechnologies to develop an expressed RNAi-based treatment for chronic hepatitis B infection.

In July, Benitec first announced that it had agreed to work with Biomics on the therapy (see RNAi News, 7/16/2009). Now, the companies have “put together the final project plan, budgets, and agreements” for the HBV effort, Benitec CEO Sue MacLeman said in a statement.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.